Li-Tzong Chen Selected Research

Leucovorin (Folinic Acid)

6/2022	Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
1/2022	The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan.
1/2022	Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study.
1/2022	A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study.
1/2021	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
1/2021	Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study.
2/2020	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
1/2020	The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
1/2020	Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
1/2020	Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Li-Tzong Chen Research Topics

Disease

92	Neoplasms (Cancer) 06/2022 - 09/2002
34	Pancreatic Neoplasms (Pancreatic Cancer) 06/2022 - 03/2006
25	Adenocarcinoma 06/2022 - 11/2013
16	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 01/2003
14	Stomach Neoplasms (Stomach Cancer) 11/2021 - 01/2002
14	Lymphoma (Lymphomas) 01/2020 - 06/2003
13	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 02/2022 - 08/2004
13	Disease Progression 10/2021 - 09/2005
13	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 12/2019 - 12/2006
10	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2013
9	Carcinogenesis 01/2022 - 02/2012
7	Carcinoma (Carcinomatosis) 04/2019 - 07/2004
6	Biliary Tract Neoplasms (Biliary Tract Cancer) 10/2021 - 07/2015
6	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020 - 09/2005
6	B-Cell Lymphoma (Lymphoma, B Cell) 04/2019 - 10/2008
5	Neutropenia 10/2021 - 01/2002
5	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2004
5	Infections 01/2021 - 09/2005
5	Nasopharyngeal Carcinoma 03/2014 - 07/2002
4	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2021 - 12/2016
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2019 - 10/2016
3	Adenocarcinoma of Lung 01/2022 - 06/2015
3	Febrile Neutropenia 01/2022 - 01/2002
3	Thrombocytopenia (Thrombopenia) 10/2021 - 05/2006
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 07/2021 - 07/2009
3	Primitive Neuroectodermal Tumors (PNET) 01/2021 - 11/2017
3	Hemorrhage 01/2021 - 11/2005
3	Fever (Fevers) 01/2020 - 05/2006
3	Necrosis 02/2017 - 07/2004
3	Hepatitis B 01/2016 - 06/2010
2	Cholangiocarcinoma 10/2022 - 01/2018
2	Liver Neoplasms (Liver Cancer) 05/2022 - 07/2014
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 07/2011
2	Splenomegaly 01/2022 - 09/2005
2	Sepsis (Septicemia) 01/2022 - 10/2021
2	Fatigue 01/2021 - 02/2016
2	Exanthema (Rash) 01/2020 - 02/2012
2	Sarcoma (Soft Tissue Sarcoma) 08/2019 - 12/2014
2	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 03/2015

Drug/Important Bio-Agent (IBA)

30	Leucovorin (Folinic Acid)FDA Link 06/2022 - 01/2002
30	Fluorouracil (Carac)FDA LinkGeneric 06/2022 - 01/2002
28	Gemcitabine FDA Link 01/2022 - 03/2006
20	Irinotecan (Camptosar)FDA LinkGeneric 06/2022 - 02/2016
14	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 01/2004
13	Proteins (Proteins, Gene)FDA Link 04/2022 - 04/2012
11	Imatinib Mesylate (Gleevec)FDA Link 01/2019 - 12/2006
10	Thalidomide (Thalomid)FDA Link 02/2022 - 01/2003
9	NivolumabIBA 01/2022 - 12/2017
9	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2012
8	Phosphotransferases (Kinase)IBA 04/2021 - 01/2008
8	Everolimus FDA Link 11/2017 - 05/2011
6	Anti-Bacterial Agents (Antibiotics)IBA 02/2022 - 09/2005
6	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 01/2002
6	Messenger RNA (mRNA)IBA 08/2017 - 04/2012
5	CateninsIBA 02/2022 - 01/2019
5	ErbB Receptors (EGF Receptor)IBA 01/2022 - 02/2012
5	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2013
5	Pharmaceutical PreparationsIBA 01/2022 - 09/2011
5	Capecitabine (Xeloda)FDA Link 01/2022 - 07/2011
5	EnzymesIBA 01/2021 - 09/2016
4	Sorafenib (BAY 43-9006)FDA Link 05/2022 - 12/2013
4	Antineoplastic Agents (Antineoplastics)IBA 02/2022 - 07/2002
4	5- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA 07/2021 - 10/2014
4	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2019 - 01/2008
4	7-hydroxy-6-methoxyphthalide (MA-1)IBA 02/2017 - 11/2011
3	RamucirumabIBA 10/2021 - 10/2017
3	ADI PEG20IBA 01/2021 - 06/2013
3	Biological ProductsIBA 01/2020 - 01/2016
3	Cetuximab (Erbitux)FDA Link 06/2019 - 09/2014
3	AntigensIBA 04/2019 - 10/2013
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 04/2019 - 11/2017
3	Arginine (L-Arginine)FDA Link 12/2017 - 06/2013
3	MTOR InhibitorsIBA 11/2017 - 05/2011
3	Docetaxel (Taxotere)FDA Link 01/2016 - 01/2002
3	PlatinumIBA 01/2016 - 07/2009
3	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 11/2003
3	Indicators and Reagents (Reagents)IBA 02/2014 - 04/2012
3	NF-kappa B (NF-kB)IBA 10/2008 - 09/2004
3	ParaffinIBA 01/2008 - 09/2004
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 02/2022 - 03/2014
2	Semaphorins (Semaphorin)IBA 02/2022 - 01/2022
2	MicroRNAs (MicroRNA)IBA 01/2022 - 10/2015
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
2	Protein Kinases (Protein Kinase)IBA 04/2021 - 03/2014
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2021 - 12/2009
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2021
2	pembrolizumabIBA 01/2021 - 11/2018
2	Immunoglobulin G (IgG)IBA 01/2020 - 12/2017
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 04/2019 - 12/2017
2	Cytotoxins (Cytolysins)IBA 04/2019 - 12/2017
2	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 01/2019 - 12/2018

Therapy/Procedure

55	Therapeutics 04/2022 - 01/2004
32	Drug Therapy (Chemotherapy) 02/2022 - 06/2003
5	Radiotherapy 02/2022 - 01/2004
4	Chemoradiotherapy 01/2022 - 12/2011
3	Salvage Therapy 01/2022 - 12/2011
3	Neoadjuvant Therapy 01/2022 - 08/2012
3	Induction Chemotherapy 01/2022 - 12/2011
2	Immunotherapy 10/2022 - 11/2018
2	Drug Tapering 01/2021 - 01/2021